Patient_Reported_Outcome_Measures_in_Rheumatic_Diseases

76

Table 3.6 Median levels of all patients for erythrocyte sedimentation rate (ESR), 3 (0–10)
MDHAQ scores for physical function, pain, and patient global estimate and composite routine
assessment of patient index data (RAPID3) scores at initiation of methotrexate 1996–2001 and
mean of 2.6 years later in (A) 30 incomplete responders initiating biologic agent, and (B) 63
“control” adequate responders continuing Methotrexate [ 101 ]

A. 30 Incomplete

responders

B. 63 Adequate responders

(“Controls”)

MTX start Biologic start MTX start Follow-up (NO biologic)

ESR (mm/h) 28 18 24 16

MDHAQ-function (0–10) 3.2 3.3 2.3 1.0

Pain (0–10) 5.2 6.8 4.1 1.4

Patient global (0–10) 5.5 5.5 4.2 0.9

RAPID3 (0–30) 14.9 16.2 10.6 3.6

PATGL

PAIN

HAQ-FN

ESR/CRP

DOCGL

SJC

TJC

C

D

0%

33%

33%

56%

56%

56%

78%

0% 20% 40% 60% 80% 100%

3 Highest Relative Efficiencies

0% 20% 40% 60% 80% 100%

56%

22%

33%

11%

56%

22%

0%

PATGL

PAIN

HAQ-FN

ESR/CRP

DOCGL

SJC

TJC

2 Highest Relative Efficiencies

Fig. 3.8 (continued)

T. Pincus et al.